|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 278, Issue 1, 645-650, January 3, 2003
From the Life Sciences Division, United States Surgical
Corporation, North Haven, Connecticut 06473
Trans-4-hydroxyproline (Hyp)
in eukaryotic proteins arises from post-translational modification of
proline residues. Because the modification enzyme is not present in
prokaryotes, no natural means exists to incorporate Hyp into proteins
synthesized in Escherichia coli. We show here that under
appropriate culture conditions Hyp is incorporated co-translationally
directly at proline codons in genes expressed in E. coli.
The use of Hyp by E. coli protein synthesis machinery under
typical culture conditions is not adequate to support protein
synthesis; however, intracellular concentrations of Hyp sufficient to
compensate for the poor use are achieved in media with hyperosmotic
sodium chloride concentrations. Hyp incorporation was demonstrated in
several recombinant proteins including human Type I collagen
polypeptides. A fragment of the human collagen Type I (
Present address: Achillion Pharmaceuticals, New Haven, CT 06511.
§
Present address: Pfizer Corporation, Groton, CT 06340.
Present address: Alexion Pharmaceuticals, Cheshire, CT 06410.
¶
Present address: Bayer Corporation, West Haven, CT 06516.
**
To whom correspondence should be addressed: Acorda Therapeutics,
Inc., 15 Skyline Drive, Hawthorne, NY 10532. Tel.: 914-347-4300, ext.
139; E-mail: egruskin@acorda.com.
Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc. This article has been cited by other articles:
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||